Gain Therapeutics, Inc. Common Stock (GANX) Stock
Fundamentals
Recent news

Why Is GANX Stock Rallying 22% After Hours?
Why Is GANX Stock Rallying 22% After Hours?
GANX

Best Momentum Stocks to Buy for January 9th
Best Momentum Stocks to Buy for January 9th
GANX
Technicals
Analyst Ratings
Financials
Performance
No data available
Debt & Balance Sheet
No data available
Revenue to Profit
No data available
Earnings
No data available
% positive news of 2 articles
published over the past 14 days
Latest news

Why Is GANX Stock Rallying 22% After Hours?
Why Is GANX Stock Rallying 22% After Hours?
GANX

Best Momentum Stocks to Buy for January 9th
Best Momentum Stocks to Buy for January 9th
GANX
About Gain Therapeutics, Inc. Common Stock
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Khalid Islam Ph.D. | Chairman & Founder | 1955 |
| Mr. Gene Mack M.B.A. | President, CEO & Director | 1974 |
| Mr. Gianluca Fuggetta | Senior VP of Finance & Principal Financial Officer | 1989 |
| Dr. Terenzio Ignoni Pharm.D. | Chief Operating Officer | — |
| Dr. Joanne Taylor Ph.D. | Chief Scientific Officer | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
2 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.2 | -2.6 | +3.7 | +3.6 | -15.6 | +2.9 | +0.6 |



